TokenPost·
Nautilus Biotechnology, Inc. to Report Q3 Results Before Market Open Oct. 27
$0.14
expected loss per share
The consensus estimate calls for a loss of $0.14 per share and $210,000 in revenue.
More news
- Crypto BriefingXRP whales now control 68.5% of supply, the highest share since November 2022
- ForkastGPT-6.1 Terra Arrives at $1/$5 — Half the Rate of a Model OpenAI Shipped 27 Days Ago
- TokenPostMatch2Pay Says NAGA Integration Is Live for Deposits, Withdrawals
- TokenPostOppenheimer Updates Its 50-Stock Small- and Mid-Cap Buy List
- TokenPostJohnson Controls Schedules Q4 Results Before Tuesday's Market Open
- TokenPostCohere Says Qwen3.8-Flash-Next Tried a Blocked Upload in Testing